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Abstract
Background: The 3-dimensional (3D) microenvironment of breast carcinomas is characterized by profoundly
altered pH homeostasis, reflecting increased metabolic acid production and a confined extracellular space
characterized by poor diffusion, yet the relative contributions of specific pH-regulatory transporters to 3D growth
are poorly understood. The aim of this work was to determine how 3D spheroid growth of breast cancer cells
impacts the expression and spatial organization of major acid extruding proteins, and how these proteins in turn
are required for spheroid growth.
Methods: MCF-7 (Luminal-A) and MDA-MB-231 (Triple-negative) human breast cancer cells were grown as
~700-950 μm diameter spheroids, which were subjected to Western blotting for relevant transporters (2- and 3D
growth), quantitative immunohistochemical analysis, and spheroid growth assays. Individual transporter
contributions were assessed (i) pharmacologically, (ii) by stable shRNA- and transient siRNA-mediated knockdown,
and (iii) by CRISPR/Cas9 knockout.
Results: In MCF-7 spheroids, expression of the lactate-H+ cotransporter MCT1 (SLC16A1) increased from the
spheroid periphery to its core, the Na+,HCO3
− cotransporter NBCn1 (SLC4A7) was most highly expressed at the
periphery, and the Na+/H+ exchanger NHE1 (SLC9A1) and MCT4 (SLC16A3) were evenly distributed. A similar
pattern was seen in MDA-MB-231 spheroids, except that these cells do not express MCT1. The relative total
expression of NBCn1 and NHE1 was decreased in 3D compared to 2D, while that of MCT1 and MCT4 was
unaltered. Inhibition of MCT1 (AR-C155858) attenuated MCF-7 spheroid growth and this was exacerbated by
addition of S0859, an inhibitor of Na+,HCO3
− cotransporters and MCTs. The pharmacological data was recapitulated
by stable knockdown of MCT1 or NBCn1, whereas knockdown of MCT4 had no effect. CRISPR/Cas9 knockout of
NHE1, but neither partial NHE1 knockdown nor the NHE1 inhibitor cariporide, inhibited MCF-7 spheroid growth. In
contrast, growth of MDA-MB-231 spheroids was inhibited by stable or transient NHE1 knockdown and by NHE1
knockout, but not by knockdown of NBCn1 or MCT4.
Conclusions: This work demonstrates the distinct expression and localization patterns of four major acid-extruding
transporters in 3D spheroids of human breast cancer cells and reveals that 3D growth is dependent on these
transporters in a cell type-dependent manner, with potentially important implications for breast cancer therapy.
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Background
Cells in a solid tumor function in an environment funda-
mentally different from that of cells in normal tissues,
which profoundly affects the gene expression profile and
functional properties of the cancer cells. This has been
demonstrated both for physico-chemical conditions in the
tumor microenvironment [1] and for the 3-dimensional
(3D) tumor architecture [2, 3]. Comparisons of 2D- and
3D culture of cancer cells have demonstrated that the
phenotype of 3D spheroids much more closely mimic that
of in vivo tumors [4, 5]. The specific tumor microenviron-
ment conditions differ between cancer forms, but gener-
ally comprise hypoxia and/or anoxia, reduced glucose and
ATP levels, elevated extracellular lactate levels, and acidic
extracellular pH (pHe) [6–8]. In addition to hypoxia, the
Warburg effect, i.e. a shift from oxidative phosphorylation
towards glycolysis even in the presence of sufficient oxy-
gen, is characteristic of most cancer cells, favoring pre-
dominant use of glycolytic metabolism [9]. Elevated rates
of glycolysis and ATP hydrolysis cause the highly prolifer-
ative and anabolic cancer cells to produce more acid than
normal cells [7]. As a slightly alkaline intracellular pH
(pHi) value is a prerequisite for growth, proliferation, sur-
vival and motility [10, 11], cancer cells must initiate strat-
egies to circumvent intracellular acidification.
Mediators of increased acid extrusion in tumor cells
include the Na+/H+ exchanger NHE1 (SLC9A1), the
Na+,HCO3
− cotransporter NBCn1 (SLC4A7), the lacta-
te,H+ cotransporters of the monocarboxylate trans-
porter family, MCT1 and MCT4 (SLC16A1 and −3),
and, in some cells, V-type H+-ATPases [8, 12–14]. We
and others have previously demonstrated upregulation
of these transporters in human cancers [8, 15–18].
Specifically, we recently reported the strong upregula-
tion of NBCn1 by the major breast cancer oncogene
ErbB2 [12, 19], and genome-wide association studies
(GWAS) have consistently demonstrated association of
a SNP in the NBCn1 3’ untranslated region with increased
risk of breast cancer [20]. In vivo studies demonstrated
roles for MCTs and NHE1 [13, 21] and our own recent
work identified an important role for NBCn1 [22] in
tumor growth.
Altered pH homeostasis plays central roles in many as-
pects of tumor progression [6–8, 10], and studies in 2D
monoculture have implicated specific pH-regulatory ion
transporters in control of e.g. metabolism, motility, and
chemotherapy resistance in a wide range of cancer cell
lines [12, 23–25]. However, regulation of pHi in solid tu-
mors differs profoundly from that in 2D culture, and
major regional differences and dynamic changes in the
roles of pH-regulatory proteins as the tumor grows can
be envisaged. Elegant studies of 3D tumor spheroids
have demonstrated the predicted gradient of increasing
extracellular acidity toward the spheroid core [26], but
detailed studies of the spatial organization of individual
pH-regulatory transporters and of their contributions to
spheroid growth are lacking.
The aim of the present study was to provide, for the
first time, a detailed analysis of the impact of 3D growth
on expression and localization of pH-regulatory ion
transporters, and determine how these transporters in
turn impact on 3D growth of breast cancer cells. We
show that 3D spheroid growth impacts on the relative
expression of acid-extruding transporters, and that
NHE1, NBCn1, MCT1 and MCT4 exhibit distinct
spatial organization within MCF-7 and MDA-MB-231
breast cancer cell spheroids. Furthermore, we show that
3D growth of MCF-7 cells is predominantly dependent
on NBCn1 and MCT1, while that of MDA-MB-231 cells
is highly dependent on NHE1. Thus, we demonstrate that
acid-extruding transporters exhibit distinct localization
patterns in breast cancer spheroids and are important for
their growth in a cell-type dependent manner, with poten-
tially important implications for breast cancer therapy.1
Methods
Antibodies and reagents
The following antibodies were purchased from Cell Sig-
naling: Ezrin/Radixin/Moesin (#3142), PARP (#9542) and
cleaved PARP [Asp214] (#5625). NHE1 (#sc-136239),
MCT4 (#sc-50329) and ZO-1 (#sc-10804) were from
Santa Cruz Biotechnology, and MCT1 (#AB3538P) from
Millipore. E-cadherin (#610181) and p150 [Glued]
(#610473) were from BD Transduction Laboratories and
CAIX (M75, [28]) was from BioScience, Slovakia. The
NBCn1 antibody was a kind gift from Jeppe Praetorius,
Aarhus University, Denmark, and the polyclonal NHE1
antibody (Xb-17) was a kind gift from Mark Musch,
University of Chicago, IL. Antibody against the S703-
phosphorylated NHE1 was from DSTT, University of
Dundee, Ireland. β-actin (#A5441), anti-Mouse (#A1293)
and anti-Rabbit (#A3937) alkaline phosphatase-conjugated
secondary antibodies were from Sigma-Aldrich. Anti-
mouse (#P0447) and anti-rabbit (#P0448) Horseradish
Peroxidase (HRP)-conjugated secondary antibodies were
from Dako. Cariporide and S0859 were kind gifts from
Sanofi-Aventis. AR-C155858 was acquired from AdooQ
BioScience, Irvine, CA, USA. The Hydroxyprobe-1 kit
including Pimonidazole and anti-pimonidazole mouse
monoclonal antibody was purchased from Hydroxyp-
robe, Inc., Burlington, MA, USA.
Cell lines and general cell culture
MCF-7 (a kind gift from Dr. Lone Ronnov-Jessen, Uni-
versity of Copenhagen) and MDA-MB-231 cells (a kind
gift from Dr. Marie Kveiborg, University of Copenhagen)
were grown in DMEM 1885-medium (incl. NaHCO3
−)
(Panum 22-2-24, #015) supplemented with 6 % FBS for
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MCF-7 cells and 10 % FBS for MDA-MB-231 cells
(Gibco, #10 106–177), 1 % Pen/Strep (Invitrogen,
#15140-148), and 1 % MEM Non-Essential Amino Acids
100× (Gibco/Invitrogen, #11140-035). Cell cultures were
discarded when they reached passage 22. For growth of
stabile shRNA knock down cell lines of MCF-7 and
MDA-MB-231, the medium was additionally supple-
mented with 1 μg/mL Puromycin (Gibco, #A11138-02).
Cells were grown at 37 °C, 95 % humidity, 5 % CO2 and
passaged when a confluence of 70-80 % was reached.
3D spheroid formation and corresponding 2D cultures
1000 MCF-7 or MDA-MB-231 cells were seeded per
well in round bottomed, ultra-low attachment 96-well
plates (Corning, #7007) in 200 μL DMEM 1885-
medium. MDA-MB-231 cells were centrifuged for
15 min at 750 RCF at 4 °C and both cell types were
grown for the indicated number of days (4–9) at 37 °C
with 95 % humidity and 5 % CO2. Medium for spheroids
of MDA-MB-231 cells was additionally supplemented
with 0.24 μg/μL GelTrex LDEV-Free Reduced Growth
Factor Basement Membrane Matrix (Gibco/Invitrogen,
#A1413202). For some experiments, corresponding 2D
monolayer cultures were performed: 500,000 MCF-7
cells/mL or 400,000 MDA-MB-231 cells/mL were seeded
in 10 cm Petri dishes and grown for 4 days at 37 °C with
95 % humidity and 5 % CO2.
Spheroid growth assays
Compact spheroids formed two days after the cells were
seeded in round bottomed, ultra-low attachment 96-well
plates and for the indicated experiments, Cariporide
(10 μM), S0859 (50 μM), AR-C 155858 (20 μM) and cor-
responding vehicle were added as indicated and the
spheroids were grown for additionally seven days. 100 or
150 μL medium (incl. inhibitors, when indicated for the
experiment) was exchanged every second day. Light
microscopic (Nikon, Japan or Leica MZ16, Germany)
images of the spheroids at 10× magnification were ac-
quired on the day of addition of inhibitors (day 2) and
on day 4, 7, and 9. To quantify spheroid growth, spher-
oid diameters were measured using ImageJ software. In
Figs. 5d and 6e, spheroid area was measured using the
freehand-drawing function of ImageJ. Each data point
thus represents the mean of measurements on 3–12
spheroids per condition (except for MDA-MB-231 transi-
ent knockdown and CRISPR/Cas9 knockout experiments,
where in a few cases only 2 spheroids per condition could
be measured).
Lentiviral knockdown of NHE1, NBCn1, MCT1 and MCT4
The following Mission shRNA bacterial glycerol stocks
were purchased from Sigma-Aldrich: NHE1 (NM_003047),
TRCN0000044649; NBCn1 (NM_003615), TRCN
0000043159; MCT1 (NM_003051), TRCN 0000038340;
MCT4 (NM_004207). Envelope plasmid pMD2.G and
packaging plasmids pMDLg/pRRE and pRSV-Rev, and
pLKO.1 empty vector plasmid were a kind gift from Jacob
B. Hansen, University of Copenhagen. Overnight bacterial
cultures were cultivated in LB medium incl. ampicillin
(Sigma-Aldrich, #A9518) for selection and plasmid DNA
purification was done by using a Nucleobond Xtra Midi EF
kit (Macherey-Nagel GmbH & Co. KIG, Germany) accord-
ing to manufacturer’s instructions.
Transfection of HEK293T cells
HEK293T cells were seeded in 6 cm Petri dishes and
grown to approx. 70 % confluence (one dish for each
plasmid DNA). 2.75 μg purified plasmid DNA encoding
shRNA sequences to target NHE1 (NM_003047),
NBCn1 (NM_003615), MCT1 (NM_003051), and MCT4
(NM_004207), respectively, and a pLKO.1 empty vector
plasmid was mixed with 0.75 μg pMD2.G, 0.75 μg
pMDLg/pRRE, 0.75 μg pRSV-Rev, 12.5 μl FuGENE HD
Transfection reagent (Promega, #E2311) and DMEM
basal medium was added up to 250 μl. The mixture in-
cubated 15 min at room temperature (RT) and was
added to the HEK293T cells in DMEM-1885 medium
without Pen/Strep.
Transduction of MCF-7 and MDA-MB-231 cells
The next day, medium on the HEK293T cells was
refreshed and the day after virus-containing medium
was harvested and 1.5 mL was sterile filtered through
0.45 μm filters and added to ~20 % confluent MCF-7
and MDA-MB-231 cell cultures along with 1.5 mL
medium and 4.5 μl polybrene (5 mg/mL; Sigma,
#S2667). To assure efficient transduction a parallel dish
of non-transduced MCF-7 and MDA-MB-231 cells was
included and was killed 100 % by Puromycin. Fresh
medium was added to the HEK293T cells and the same
procedure for harvesting of virus-containing medium
was repeated the next day. When the transduced MCF-7
and MDA-MB-231 cells had grown for 24 h, they were
reseeded and selection with 1 μg/mL Puromycin (Gibco,
#A11138-02) started. Medium was changed every 2–3
days to assure complete selection pressure and the cells
were split when needed.
CRISPR/Cas9 gene editing
MDA-MB-231 (1 x 106) and MCF-7 (2 x 106) cells were
transfected with 1 or 2 μg pX458 plasmid targeting exon
1 of SLC9A1 using Amaxa nucleofection (Lonza) with
the V-kit according to manufacturer’s guidelines. Transfec-
tants were cloned by limiting dilution and screened using
immunoblotting against NHE1. Mutations in SLC9A1 were
confirmed by PCR using 5’-CTGTGGCCTCTCTCCA-
CATC-3’ and 5’-TCGGAGCAAACGGGACTTAC-3’ followed
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by sequencing. A detailed description of the CRISPR/
Cas9 clones is forthcoming in a manuscript currently
in preparation.
Transient knockdown
MDA-MB-231 and MCF-7 cells were seeded in 6-well
plates and grown to approximately 70 % confluency.
MDA-MB-231 cells were treated with 100 nM siNHE1
(ON-TARGET SMARTpool, Thermo Scientific). Mock
siRNA (Sense sequence: 5′-AGGUAGUGUAAUCGC-
CUUGUU-3′, Eurofins MWG Operon, Ebersberg,
Germany) at corresponding concentrations was included
as a control. Transfections were performed using Lipo-
fectamine 2000 (Life Technologies, #11668-019) in
DMEM 1885 medium without Pen/Strep. The medium
was replaced with normal growth medium after 24 h,
and spheroid formation was initiated after another 24 h
by seeding the transfected cells in round-bottomed
ultralow attachment 96-well plates (Corning, #7007) as
described above.
Immunoblotting
2D culture
Cells were grown to 70–90 % confluency in 10 cm Petri
dishes, washed in ice-cold PBS and lysed in lysis buffer
(1 % SDS, 10 mM Tris–HCl, 1 mM NaVO3, pH 7.5,
heated to 95 °C). The cell lysates were homogenised by
sonication (PowerMED, Portland, Maine) and centri-
fuged (Micromax RF, Thermo) for 5 min at 20,000 g at
4 °C to remove cell debris.
3D culture
Spheroids were collected in Eppendorf tubes, washed
once in 1 mL ice-cold PBS and lysed in lysis buffer (1 %
SDS, 10 mM Tris–HCl, 1 mM NaVO3, pH 7.5, heated to
95 °C) for ~10 min at RT with intervals of vigorous vor-
texing. After this, the procedure for homogenization and
removal of cell debris described for 2D culture was
followed.
SDS-PAGE and immunoblotting of 2D and 3D cultures
Lysate protein content was determined (DC Protein
Assay kit, Bio-Rad), equalized with ddH2O, and
NuPAGE LDS 4x Sample Buffer (Invitrogen, #NP0007)
and Dithiothreitol (DTT) added. Proteins were separated
by SDS-PAGE under denaturing and reducing condi-
tions using precast NuPAGE 10 % Bis-Tris gels (NOVEX
by Life Technologies, #NP0302BOX) and NuPAGE
MOPS SDS Running Buffer (NOVEX by Life Technolo-
gies, #NP0001) or Criterion TGX 10 % gels (BioRad,
#567-1034 (18 wells) or #567-1035 (26 wells)) and Tris/
Glycine SDS buffer (BioRad, #161-0732), and Benchmark
protein ladder (Invitrogen, #10747-012). Separated pro-
teins were transferred to a nitrocellulose membrane
(Invitrogen, #LC2000) using NuPAGE Transfer Buffer
(NOVEX by Life Technologies, #NP0006) or to Trans-
blot Turbo 0.2 μm nitrocellulose membranes (BioRad,
#170-4159). Membranes were stained with Ponceau S
(Sigma-Aldrich, #P7170-1 L), blocked in blocking buffer
(5 % nonfat dry milk in TBST (0.01 M Tris/HCl, 0.15 M
NaCl, 0.1 % Tween 20)) for 1 h at 37 °C, incubated over-
night at 4 °C with primary antibodies diluted in blocking
buffer, washed extensively in TBST, incubated with alka-
line phosphatase- or HRP-conjugated secondary anti-
bodies diluted in blocking buffer, washed in TBST, and
developed using BCIP/NBT Phosphatase Substrate
(KPL, #50-81-08) or by chemiluminescence using Pierce
ECL Western Blotting Substrate (Thermo Scientific,
#32209), respectively. The membranes were scanned and
band intensity quantified using UN-SCAN-IT 6.1 (Silk
Scientific). Protein expression was normalized to that of
the corresponding control.
Spheroid fixation and immunohistochemistry
Spheroids were collected in Eppendorf tubes, washed
once in 1 mL ice-cold PBS, fixed in 10 % PBS buffered
formalin for 18–24 h at RT where after they were
washed twice in PBS, resuspended in a small amount of
PBS and injected into a drop of 60 °C warm 2 % agarose
solution (Bactoagar; BD, #214050). For pimonidazole
labeling, spheroids were pretreated with 100 μm pimoni-
dazole 2 h before fixation. Once the agarose had solidi-
fied at 5 °C for approx. 5 min, the drop was transferred
to an embedding cassette, embedded in paraffin and
sliced using a microtome (ZEISS, MIKROM HM 450).
Paraffin sections of spheroids were deparaffinized by
passing them through decreasing alcohol concentrations
for 3 min each: Xylene (6 min), 1:1 mixture of xylene
and 99.9 % ethanol, 99.9 % ethanol, 96 % ethanol, 70 %
ethanol, 50 % ethanol. The sections were washed in cold
water, placed in citrate buffer (0.21 % citric acid mono-
hydrate (Sigma-Aldrich, #C1909) in ddH2O, pH 6) and
irradiated in a domestic microwave oven for 3 × 5 min
with 1 min interval. After cooling to RT, the sections
were encircled using a pap pen, washed once in PBS be-
fore Tris-glycine (0.1 M glycine (AppliChem, #A3707) in
ddH2O, pH 7.4) was added for 15 min. After washing in
PBS, the sections were blocked in 5 % BSA in PBST
(0.1 % Tween) for 30 min–1 h RT and incubated over-
night at 4 °C with primary antibodies diluted in 1 % BSA
in PBST. The sections were washed in PBST (3 × 5 min),
incubated with 1 % BSA in PBST for 15 min and after-
wards with fluorophore-conjugated secondary antibodies
diluted 1:600 in 1 % BSA in PBST for 30 min RT. The
sections were washed in PBST (4 × 5 min) including
DAPI (1:1000), mounted with N-propyl gallate and
sealed with nail polish. The fluorescence-labeled proteins
were visualized using an Olympus BX63 epifluorescence
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microscope (40× or 10× objective). Subsequent image
adjustments (overlays and intensity only) were per-
formed in Adobe Photoshop CS6. Essentially no labeling
was detectable in absence of primary antibodies (not
shown). To quantify the intensity of labeling across the
spheroids, mean pixel intensity profiles through the
spheroids were calculated using ImageJ software, based
on rectangular Regions of Interest (ROIs) of 50 or
100 μm widths, going from the spheroid periphery to
core (two-three independent biological replicates per
transporter/condition). For each intensity profile, the
x-axis was set to start at zero and x-values were nor-
malized to the largest x-value resulting in an x-axis
ranging from 0–1. The intensity values (y-axis) were
likewise normalized to the largest intensity, generating
a y-axis ranging from 0–1. The resulting intensity
profiles were plotted in a scatter plot and LOWESS
curves with 20 points in the smoothing window were
drawn using GraphPad PRISM 6 in order to better
visualize trends of the data.
Statistical analysis
All data are shown as representative images or as means
with standard error of means (SEM) error bars. A two-
tailed, paired (when applicable, otherwise unpaired)
Student’s t-test was used to test for statistically signifi-
cant difference in means between two groups. One-way
analysis of variance (ANOVA) followed by Tukey’s or
Dunnett’s multiple comparisons post-test was used to
test for statistically significant differences when there
were more than two groups. (*), *, **, ***, and, **** denote
p < 0.1, p < 0.05, p < 0.01, p < 0.001 and p < 0.0001,
respectively.
Results
MCF-7 spheroids exhibit polarized growth, lumen
formation, a gradient of hypoxia, and non-homogenous
distribution of pH-regulatory transporters
While they do not form single cell-layered acini [29],
MCF-7 breast cancer cell spheroids can polarize [30]. To
characterize their polarization properties, MCF-7 spheroids
were fixed and processed for histology. Hematoxylin-eosin
(HE) staining illustrated the formation of a core of cells
with pyknotic nuclei (Fig.1a, top), in contrast to the spher-
oids formed by the more poorly differentiated MDA-MB-
231 breast cancer cells, which are more loosely organized
and completely lack a central lumen (Fig. 1a, bottom). The
lumen formation could involve apoptotic [31] or necrotic
[5] cell death in the spheroid core. To evaluate apoptosis
induction in the spheroids, we assessed PARP-1 cleavage
during spheroid growth and in 3D relative to 2D culture.
PARP-1 cleavage was increased in 3D growth relative to
2D conditions (Fig. 1bi) and during the course of spheroid
growth (Additional file 1: Figure S1A), and was most
prominent in cells adjacent to the spheroid lumen (Fig. 1bii
and Additional file 1: S1Bi). In contrast, PARP-1 cleavage
was essentially undetectable in the MDA-MB-231 spher-
oids (Additional file 1: Figure S1Bii). Expression patterns of
E-cadherin and the tight junction protein ZO-1 were ana-
lyzed to evaluate polarization (Fig. 1c). ZO-1 puncta indi-
cative of tight junctions, were visible just below the luminal
surface, while E-cadherin staining was essentially lacking at
apical membranes facing the lumen, consistent with its
prominent lateral localization. Ezrin/radixin/moesin (ERM)
protein staining confirmed the formation of an apical sur-
face toward the spheroid lumen of MCF-7 cells, while
MDA-MB-231 cells lacked a central lumen and showed
even ERM protein distribution throughout the spheroids
(Fig. 1d). Collectively, these results show that the MCF-7
spheroids are polarized with an apical lumen, while this is
not seen in the more malignant and less differentiated
MDA-MB-231 cells. Pimonidazole staining (Fig. 1e) dem-
onstrated the existence of an inwardly directed gradient of
hypoxia in both cell types, confirmed by staining for the
highly hypoxia-inducible carbonic anhydrase IX (CAIX) in
MCF-7 cell spheroids (Fig. 1f). Further corroborating the
association of CAIX expression with induction of a hyp-
oxic inner region of the spheroids, CAIX protein was un-
detectable (MCF-7) or weakly expressed (MDA-MB-231)
in 2D and at day 4 of spheroid growth but strongly induced
at day 9 in spheroids of both cell types (Additional file 1:
Figure S1Ci-ii).
The core and periphery of cancer cell spheroids have
been shown to exhibit differential pHi-regulatory proper-
ties [26]. To determine whether this involves differential
expression of individual transporters in different regions
of the spheroid, MCF-7 spheroids were sectioned and
stained for NHE1, NBCn1, MCT1 and MCT4 (Fig. 2a-d).
In MCF-7 spheroids, NHE1 and MCT4 localized homoge-
nously to cell membranes (and, in the case of MCT4, also
in intracellular compartment(s), see Discussion) through-
out the spheroids. In contrast, NBCn1 was most highly
expressed at the spheroid periphery, with staining seen
both in membranes and intracellularly, and MCT1
showed strong membrane localization and a clear gradient
of increasing expression toward the spheroid core. For
comparison, MDA-MB-231 cells (which do not express
MCT1 due to aberrant promoter methylation [32]) were
stained for NHE1, NBCn1, and MCT4 (Fig. 2e–g). The
most remarkable difference from the pattern observed
in MCF-7 spheroids was that MCT4 expression was
much more strongly membrane-localized in MDA-MB-231
spheroids (Fig. 2g).
To more precisely compare the transporter distribution
through the MCF-7 spheroids to the hypoxia gradient ob-
tained from the pimonidazole analysis shown in Fig. 1e,
mean pixel intensity profiles through the spheroids were
calculated for each transporter. The summarized profile
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analyses are shown in Fig. 2h, and individual traces in
Additional file 2: Figure S2. As seen, the distribution of
MCT1 largely follows the hypoxia gradient, while NHE1
and MCT4 are distributed evenly along the axis, and
NBCn1 exhibits the highest expression at the spheroid
periphery. To determine whether 3D growth altered the
total expression of NHE1, NBCn1, MCT1 and MCT4
compared to 2D growth, MCF-7 and MDA-MB-231
spheroids were lysed and subjected to SDS-PAGE and im-
munoblotting (Fig. 3). Relative to total protein levels, the
expression of NHE1 and NBCn1 was reduced by about
50 % in 3D compared to 2D growth, while that of MCT1
(MCF-7 cells only) and MCT4 was unaltered. Notably,
this pattern was identical between the two cell types. Post-
translational regulation of these transporters remains in-
completely characterized. The most widely studied is that
of Ser703 of human NHE1, which is phosphorylated by
the ERK effector p90RSK and is important for NHE1 acti-
vation by serum and growth factors [33]. The Ser703
phosphorylation of NHE1, relative to the total NHE1 ex-
pression, was not significantly altered by 3D- compared to
2D growth, but was significantly reduced as MDA-MB-
231 cells grew in size (Additional file 3: Figure S3).
Collectively, these results show that the four pH-regulatory
transporters exhibit distinct patterns of localization in 3D
spheroids, and that their relative expression is altered in 3D
compared to 2D growth conditions.
Growth of MCF-7 spheroids is attenuated by inhibition of
MCT1/2 and NBCn1
To pharmacologically determine the importance of the
individual transporters in 3D growth of breast cancer
cells, MCF-7 cells were grown as 3D spheroids for two
days, followed by seven days of growth in the presence
of cariporide (10 μM), S0859 (50 μM), and/or AR-
C155858 (20 μM) to inhibit NHE1, NBCs, or MCT1/2,
respectively (Fig. 4). Control spheroids grew to a diameter
of about 700 μm over the 9 days (650 μm in the presence
of DMSO as vehicle for AR-C155858). Inhibition of NHE1
by cariporide had no effect on spheroid growth. In con-
trast, MCT1/2 inhibition significantly reduced day 9
spheroid diameter (Fig. 4b, insert), and combined treat-
ment with AR-C155858 and S0859 further reduced day 9
diameter to about 550 μm, while the NBC inhibitor alone
had no effect. In general, no changes in transporter ex-
pression relative to the corresponding control conditions
were seen after inhibitor treatment (Additional file 4:
Figure S4A–C), with the exception that NBCn1 expres-
sion was increased when either of the transporters was
inhibited, similar to what is seen after NHE1 knock-
down [12]. No changes in transporter localization were
detectable after treatment with any of the inhibitors (n =
2, data not shown). Furthermore, there was no increase in
PARP cleavage in AR-C155858- and S0859-treated spher-
oids compared to control, in fact PARP cleavage was
decreased in AR-C treated spheroids (Additional file 4:
Figure S4D).
Knockdown of MCT1 or NBCn1, and complete knockout
of NHE1, inhibits growth of MCF-7 spheroids
While cariporide and AR-C155858 are considered highly
specific for NHE1 and MCT1, respectively, there is cur-
rently no commercially available specific inhibitor of
MCT4, and S0859 was recently reported to also inhibit
MCTs [54]. To validate the pharmacological data, each
transporter was therefore next stably knocked down in
MCF-7 cells, which were then subjected to spheroid
growth as above. Knockdown efficiencies were approxi-
mately 50, 80, 75 and 80 %, respectively, for NHE1,
NBCn1, MCT1 and MCT4 (Fig. 5a). Representative
images and summarized growth curves are shown in
Fig. 5b–c. As seen, spheroid diameter at day 9 was sig-
nificantly reduced by knockdown of MCT1, and knock-
down of NBCn1 had a numerically similar but not quite
statistically significant effect. In contrast, knockdown of
NHE1 or MCT4 had no detectable effect on spheroid
growth (Fig. 5c). While knockdown of MCT1 or NBCn1
was rather efficient (75–80 %) and inhibited growth, and
the effect was similar to that of the corresponding
pharmacological agents, NHE1 knockdown was less effi-
cient (50 %), and the lack of effect of NHE1 inhibition or
knockdown was puzzling, given the previously reported
roles of this transporter in cancer cell proliferation and
growth [10, 14]. We therefore performed a full CRISPR/
Cas9 knockout of NHE1 in MCF-7 cells (Additional file
5: Figure S5B), and grew these cells as spheroids as
(See figure on previous page.)
Fig. 1 Characterization of MCF-7 and MDA-MB-231 spheroids. Sections of MCF-7 and MDA-MB-231 spheroids that were grown for 9 days (a, bii, c,
d, e and f) followed by PFA fixation, embedding, and histological and immunohistochemical analysis (IHC). a: Hematoxylin and eosin (H&E) staining. b:
MCF-7 spheroids (3D) and 2D cultures were grown for 4 days in parallel followed by lysis and Western blotting with PARP antibodies. Top panel shows
representative Western blots, while panel bi shows quantifications of band intensities normalized to that of corresponding 2D culture. Error bars denote
SEM. 8 n. A two-tailed, paired Student’s t-test was used to test for statistically significant difference in means between the two groups. * indicates p< 0.05.
Panel bii shows a section of a MCF-7 spheroid stained with antibodies recognizing cleaved PARP (c-PARP) only. Dashed lines indicate spheroid boundaries
and arrowheads indicate c-PARP positive nuclei. Scalebar: 20 μm. c: ZO-1 and E-cadherin staining of MCF-7 spheroids. Arrowheads indicate ZO-1 puncta.
Scalebars: 20 μm. d: Ezrin/Radixin/Moesin (ERM) staining. Scalebar: 20 μm. e and f: Pimonidazole (Pim) and CA IX staining was used to
detect hypoxic regions. Scalebars: 100 μm and 20 μm, respectively. All images are representative of 4–5 n, except for data in d-right and
e, which represent 3n. L, P and C: indicate lumen, periphery and core, respectively, of spheroids
Andersen et al. Molecular Cancer  (2016) 15:45 Page 7 of 18
BA
C MCT1 DAPIMerge
L
D
NHE1
L
DAPI
Merge
NBCn1
L
DAPI
Merge
MCT4
L
DAPI
Merge
NHE1 DAPI
Merge
NBCn1 DAPI
MergeFE
MCT4 DAPI
Merge
G
0.0                             0.5                             1.0
0.0
0.5
1.0
R
el
at
iv
e 
in
te
n
si
ty
MCT1
NHE1
NBCn1
eroCPeriphery
Hypoxia
MCT4
H
Fig. 2 (See legend on next page.)
Andersen et al. Molecular Cancer  (2016) 15:45 Page 8 of 18
above. Indeed, in contrast to the lack of effect of the
50 % knockdown (Fig. 5c), full knockout of NHE1 sig-
nificantly retarded spheroid growth compared to that of
wild-type MCF-7 cells (Fig. 5d).
Knockdown of NHE1 inhibits growth of MDA-MB-231
spheroids
The activity and expression levels of different pH-regulatory
transporters vary widely between different cancer cell types
[26, 34, 35]. We therefore next asked whether spheroid
growth of another widely used human breast cancer model,
the highly invasive MDA-MB-231 cells which represent the
triple-negative breast cancer subtype, was affected by stable
knockdown of NHE1, NBCn1, or MCT4 (as noted above,
MCT1 is not expressed in MDA-MB-231 at detectable
levels, [32]). Stable knockdown of all three transporters was
obtained, with knockdown efficiencies of about 85, 70 and
70 %, respectively, for NHE1, NBCn1, and MCT4, and no
detectable compensatory upregulation of the transporters
studied (Fig. 6a). Xenograft tumors grown from these cells
were recently shown to be strongly growth-attenuated by
NHE1 knockdown [36]. In congruence with this, NHE1
knockdown significantly reduced MDA-MB-231 spheroid
diameter at day 9, while knockdown of NBCn1 or MCT4
had no effect (Fig. 6b–c). To further substantiate this find-
ing, we also evaluated the effect of transient knockdown of
NHE1 in MDA-MB-231 cells with an unrelated NHE1
siRNA sequence (Fig. 6d; knockdown was stable for at least
120 h, Additional file 5: Figure S5A), and of CRISPR/Cas9
knockout of NHE1 in MDA-MB-231 cells (Fig. 6e,
Additional file 5: Figure S5B), both of which signifi-
cantly reduced spheroid growth. In contrast, addition
of cariporide had no effect (Additional file 6: Figure
S6; see Discussion).
Collectively, the results in Figs. 4, 5, and 6 show that
acid-extruding ion transporters are important for 3D
spheroid growth of breast cancer cells. The specific acid
extruder(s) involved are cell-type dependent, with
MCT1 and NBCn1 playing important roles in MCF-7
cells, and NHE1 apparently playing a greater role in
MDA-MB-231 cells, although the more efficient knock-
down in these cells should be taken into account.
Discussion
Acid–base homeostasis is dysregulated in cancer cells
and conditions for pH regulation are fundamentally
different in 3D compared to 2D environments. Here, we
show that localization and/or expression of four major
net acid extruding transporters – NHE1, NBCn1, MCT1
and MCT4 – are regulated during growth of breast can-
cer spheroids and that these transporters contribute to
breast cancer spheroid growth in a cell-type dependent
manner.
General properties of MCF-7 spheroids
While in vivo tumors are obviously much more complex
than cancer cell spheroids in terms of architectural and
cellular diversity, spheroids resemble in vivo tumors
much more closely than 2D cultures with respect to
multiple parameters, and are excellent models of 3D
growth [4, 5]. Normal mammary epithelial cells can be
induced to form acini in 3D culture, resembling the na-
tive mammary duct structure [29, 31]. With increasing
aggressiveness, organization is lost, resulting in the for-
mation of solid spheroids [31, 37] and at larger sizes
often a necrotic core [5]. The observation of a central
cavity in such a spheroid can thus reflect lumen forma-
tion, generally characterized by apoptosis [31] or necrotic
core formation due to hypoxia. MCF-7 cell spheroids lack
lumen formation after 1–2 days of growth ([29] and APA
and SFP, unpublished data), but we show here that contin-
ued spheroid growth of MCF-7 cells is associated with
partial polarization and formation of a large lumen lined
by apical markers and tight junctions, and a progressive
increase in PARP cleavage which was most prominent
close to the lumen. MDA-MB-231 spheroids were more
loosely organized and lacked lumen and detectable PARP
cleavage, yet both MCF-7 and MDA-MB-231 cell
spheroids exhibited a clear gradient of increasing hypoxia
towards the lumen.
Acid-extruding transporters are differentially distributed
in MCF-7 spheroids, and their expression is altered in 3D
compared to 2D
In both MCF-7 and MDA-MB-231 cells, expression of
NHE1 and NBCn1 relative to total protein was reduced
in 3D compared to 2D, while that of MCT1 and MCT4
was unaltered. The precise changes in the 3D setting
underlying this difference require further investigation,
yet it is well known that the expression of many tran-
scription factors, cytokines, cytoskeletal proteins and
other factors potentially relevant to the expression of the
(See figure on previous page.)
Fig. 2 Localization profiles of NHE1, NBCn1, MCT1 and MCT4 in MCF-7 and MDA-MB-231 spheroids. Sections of MCF-7 (A-D) and MDA-MB-231 (E-G)
spheroids that were grown for 9 days followed by PFA fixation, embedding, and immunohistochemical analysis (IHC). a and e: NHE1 staining. b and f:
NBCn1 staining. c: MCT1 staining. d and g: MCT4 staining. Images are representative of 3–5 n. Scalebars: 20 μm. L: indicates lumen of
spheroid. h: Relative distribution of the transporters NHE1, NBCn1, MCT1 and MCT4 from the periphery towards the core (across the viable
region) of MCF-7 spheroids. Based on two mean pixel intensity profiles per spheroid on three spheroids (only two for MCT1) from independent
biological replicates per transporter/antibody (For details, see Methods)
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transporters studied here, differs profoundly between 2-
and 3D conditions [2, 38, 39], underscoring the import-
ance of studying their roles in a 3D setting. Furthermore,
whereas NHE1 and MCT4 appeared uniformly distributed
throughout the MCF-7 cell spheroids, NBCn1 expression
was most prominent in the spheroid periphery and, con-
versely, MCT1 expression exhibited an inward-directed
gradient which largely coincided with the measured gradi-
ent of hypoxia. It was also notable that whereas MCT4
expression was essentially fully membrane-localized in
MDA-MB-231 cell spheroids, MCT4 was partially local-
ized to intracellular compartment(s) in MCF-7 cells.
While not further pursued here, this may reflect differen-
tial expression of proteins contributing to MCT4 mem-
brane localization in the two cell lines [40, 41].
To our knowledge, ours is the first study to address
how transporter localization is regulated by spheroid
growth. In patient breast cancer tissue, we found NHE1
to be most highly expressed in well-perfused, peripheral
tumor regions, while NBCn1 expression did not exhibit
a detectable spatial gradient [15]. In brain tumors, NHE1
was most highly expressed at the periphery, whereas
MCT1 and −4 showed a broader distribution [42]. In xe-
nografts of colorectal and cervical cancer cells, MCT1 was
A
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Fig. 3 NHE1, NBCn1, MCT1 and MCT4 expression in MCF-7 and MDA-MB-231 spheroids relative to 2D culture. MCF-7 and MDA-MB-231 spheroids
(3D) and 2D cultures were grown 4 days in parallel, followed by lysis and Western blotting with antibodies directed against the specific transporters.
Top panels in a, b, c and d show representative Western blots, while lower panels show quantifications of band intensities normalized to that of
corresponding 2D culture. a: NHE1 (MCF-7: 5n, MDA-MB-231: 3n). b: NBCn1 (MCF-7 and MDA-MB-231: 3n). c: MCT4 (MCF-7 and MDA-MB-231: 3n). d:
MCT1 (3n). Error bars denote SEM. A two-tailed, paired Student’s t-test was used to test for statistically significant difference in means between the two
groups. * and *** indicate p < 0.05 and p < 0.001, respectively
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found in the tumor periphery [43]. In our hands, expres-
sion of MCT1, but not MCT4, followed the gradient of
hypoxia in the spheroids. Functionally, the high MCT1 ac-
tivity at the hypoxic spheroid core agrees well with the fact
that glycolytic metabolism dominates in this region. What
upregulates MCT1 expression in this region remains to be
elucidated, since the majority of studies on this topic have
shown that MCT4, yet not MCT1, is hypoxia-inducible
(e.g. [44, 45]). There are however reports of MCT1 upreg-
ulation by hypoxia in cancers [46], possibly due to the
additional presence of a glucose deprivation gradient [47],
a situation also present in spheroids [5]. Interestingly, it
was recently reported that while MCT1 expression was
unaltered, its activity was increased under hypoxia due to
the hypoxic upregulation of CAIX [45].
It is tempting to suggest that the observed distribution
of NHE1 and NBCn1 is reflected in different subcellular
contributions to pHi regulation and hence to growth, al-
though it should be kept in mind that due to extensive
posttranslational regulation, expression levels per se say
little about transporter function. Ser703 of human
NHE1 has been widely implicated in regulation of NHE1
activity [33], and we recently demonstrated its phos-
phorylation in breast cancer cells in response to prolac-
tin [48]. Relative NHE1 Ser703 phosphorylation was
largely unaffected by 3D growth, except for a decrease in
MDA-MB-231 cells with time of spheroid growth. Thus,
Ser703-dependent NHE1 activity may be reduced in
MDA-MB-231 spheroids during long-term growth.
NHE1 was previously found to play a major functional
Day 2 (0) Day 4 (2) Day 7 (5) Day 9 (7)
Ctrl.
DMSO
S0859
AR-C
S0859 + AR-C
A B
Cariporide
µ
Fig. 4 Effect of pharmacological inhibitors of NHE1, NBCn1, and MCT1 on MCF-7 spheroid growth. MCF-7 spheroids were treated with inhibitors
of NHE1 (Cariporide, 10 μM), NBC (S0859, 50 μM), and MCT1 (AR-C, 20 μM) on day 2 and their growth was monitored for seven days (until day 9).
a: Representative light microscopic images of the spheroids (10×) on day 2, 4, 7 and 9. Scalebar: 100 μm. Numbers in parentheses indicate
number of days treated with the respective inhibitors. b: Quantification of spheroid diameters shown in a. n = 3-5. Error bars denote SEM. The
horizontal dashed line indicates the mean diameter of all spheroids on day 2. There was no statistical significant difference in spheroid diameter
between the groups on day 2 (tested by a one-way ANOVA with Tukey’s multiple comparisons post-test). The dotplot insert shows diameters on day
9. Mean and SEM are indicated. One-way ANOVA with Dunnett’s multiple comparisons post-test was used to test for statistically significant differences
between treatment groups and their respective vehicle control (Ctrl./DMSO). * indicates p-value < 0.05
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role in pHi regulation in the periphery of cancer spher-
oids, and HCO3
− dependent mechanisms in the core
[26]. However, the role of HCO3
− in the core at least in
part reflects its role as a mobile buffer, rather than as a
substrate for Na+,HCO3
− cotransporters [26]. Given the
importance of NBCn1 in breast cancer [12, 15, 22] we
focus on this isoform here. A full analysis of all HCO3
−
transporters is beyond the scope of this work, but would
be needed to precisely map their contributions and activ-
ity, but roles of other isoforms are clearly also likely ([53]
and discussion below). Similar to MCT1, the mechanisms
causing NBCn1 to be most strongly expressed in the
spheroid periphery remain to be determined, but likely
regulators would be the gradients of hypoxia, lactate, pHe,
pHi, and ATP arising in spheroids [5].
It should be noted that other acid–base transporters
than the four studied here may play a role in 3D growth,
depending on the cell type and conditions. For instance,
pharmacological inhibitors or knockdown of proton
ATPases have been shown to reduce growth of some
cancer cells [49], and such compounds are currently in
clinical trials [50]. Finally, while not further studied here,
it is worth noting that the marked upregulation of CAIX
as well as its specific localization to the inner regions of
the spheroids, may also be important for the regulation
of spheroid growth, given its known importance for pH
homeostasis in the confined 3D space of spheroids [51].
Growth of breast cancer spheroids is dependent on acid
extruding ion transport proteins
A major conclusion of this work is that acid-extruding
transporter(s) are important for spheroid growth yet that
the specific transporters that play the predominant roles
differ between breast cancer subtypes. This suggests that
what is required to maintain 3D growth is the phenotype
of acid extrusion rather than a given transporter protein,
posing the challenge to therapeutic use that the relevant
target(s) will likely differ between breast cancer subtypes,
a notion corroborated by the differences between MCF-
7- (luminal A) and MDA-MB-231 (triple-negative) cell
spheroids revealed by the present work. Although
complete knockout of NHE1 reduced spheroid growth
in both cell lines, partial knockdown of NHE1 only re-
duced growth for MDA-MB-231 spheroids, and growth
of MCF-7 spheroids was also delayed by knockdown of
NBCn1 or MCT1 or by pharmacological inhibition of
MCT, exacerbated by concomitant inhibition of NBCs.
The role of MCT1 in spheroid growth is well in line
with previous reports from in vivo studies of tumor
growth [13, 16, 21]. The role for NBCn1 corroborates
previous reports from us and others demonstrating its
upregulation in human breast cancer patients [15] and
the importance of NBCs in mammary tumor pHi regula-
tion and in vivo tumor formation [14, 22]. In conjunc-
tion with GWAS reports linking NBCn1 to breast
cancer risk [20], this identifies NBCn1 as a target of po-
tential therapeutic interest. However, the very marked
differences in expression of the various NBC isoforms
across different cancers [52] suggests that the specific
NBC isoform relevant is likely to differ, a notion sub-
stantiated by the recently reported role of another SLC4
family member, NBCe1 (SLC4A4), in proliferation of
MDA-MB-231 cells as well as LS174 colon cancer cells
[53]. In congruence with our finding that NBCn1 ex-
pression did not follow the hypoxia gradient in the
spheroids, this study furthermore showed that NBCe1,
but not NBCn1, was upregulated by hypoxia [53]. Im-
portantly, the compound used to inhibit NBC activity,
S0859, was recently shown to also inhibit MCTs [54].
Since in our work, this compound had no effect on its
own, but was additive to the effect of the MCT1 inhibi-
tor, we favor the interpretation that NBCn1 is the main
target of inhibition in our setup. This was confirmed by
the knockdown data, however, a slight reduction in
MCT1 expression was seen after NBCn1 knockdown
(Fig. 5a), hence we cannot fully exclude a contribution
from MCT1 to the observed effect.
In contrast to MCF-7 cell spheroids, MDA-MB-231
spheroids were not dependent on NBCn1 for growth, but
depended only on NHE1 of the transporters studied here.
This is supported by early experiments on xenograft
growth of human bladder carcinoma cells [55], and recent
work demonstrating that NHE1 ablation in MDA-MB-231
cells reduces xenograft growth [36]. Dependence on
NHE1 may in part relate to glycolysis status: 50 % of
(See figure on previous page.)
Fig. 5 Roles of NHE1, NBCn1, MCT1 and MCT4 in MCF-7 spheroid growth. MCF-7 cells were transduced with lentivirus containing plasmids with
shRNA constructs targeted against NHE1, NBCn1, MCT1 or MCT4, respectively. Transduction with the empty vector pLKO.1 (pLKO.1) was used
as control. a: Western blotting with antibodies directed against the specific transporters was performed to verify knockdown of the respective
transporters. b: The transduced cell lines were grown as spheroids, and representative light microscopic images (10×) of the spheroids on day 2,
4, 7 and 9 are shown. Scalebar: 100 μm. 3n. c: Quantification of spheroid diameters shown in b. The dot-plot insert shows diameters on day 9.
Mean and SEM are indicated. One-way ANOVA with Dunnett’s multiple comparisons post-test was used to test for statistical significant differences
between pLKO.1 and the respective groups. d: NHE1 expression was ablated in MCF-7 cells by CRISPR/Cas9-mediated knockout (KO) and wild-type (WT)
and KO cells were grown as spheroids for seven days. Lower panel shows quantification of spheroid areas while the top panel shows representative
light microscopic images (10×) of the spheroids on day 2, 4 and 7. Scale bar: 100 μm. 3 n. Error bars denote SEM. A Student’s t-test (unpaired) was used
to test for statistical significant difference between the wild-type and NHE1 knockout. * indicates p < 0.05
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tumors of CCL39 cells inoculated into nude mice under-
went spontaneous regression if lacking NHE1 [21], yet
growth of non-glycolytic CCL39 cell tumors was un-
affected by the absence of NHE1 [56]. In line with this,
MDA-MB-231 cells are more dependent on glycolysis
than MCF-7 cells [57]. It is furthermore intriguing that
NHE1 has been proposed to be particularly dependent on
glycolytically derived ATP [58], suggesting that the link
between metabolic profile and NHE1 dependence should
be further explored.
Finally, despite the marked effects of transporter
knockdown or knockout, pharmacological inhibition had
no (NHE1) or limited (NBCn1) effect. The same concen-
tration of cariporide strongly attenuated growth of
BxPC-3 pancreatic spheroids (Noehr-Nielsen, A., and
SFP, unpublished), and although S0859 is very lipophilic
[59], the concentration used was previously found effect-
ive in spheroids [26] and indeed was additive to that of
MCT1 inhibition in the present study. Hence, while they
are likely less effective in spheroids than in 2D condi-
tions, it seems unlikely that the inhibitors were not func-
tional. An obvious difference between pharmacological
inhibition and knockdown in the present work is that
the inhibitors were only present from day 2 after spher-
oid formation. However, spheroids of knockdown cells
were similar in size to controls at this time, hence, eluci-
dation of this point requires further analysis.
We did not detect obvious changes in the core/lumen
area in S0859- or AR-C-treated spheroids (n = 2, data
not shown), and there was no detectable increase in
PARP cleavage in these spheroids compared to control,
hence, although this remains to be directly addressed,
we favor the interpretation that the decrease in spheroid
size mainly reflects reduced growth/proliferation. Complete
elucidation of the relation between pHi regulation and 3D
growth requires further studies. While pHi recovery after
an acid load in 2D-grown MCF-7 cells was dependent on
both NHE1 and NBCs [12], 3D growth of MCF-7
cells appeared to be more strongly dependent on
NBCn1, and only full ablation of NHE1 reduced their
growth. One interpretation of this is that hypoxia and
strong extracellular acidity in the 3D setting limits
contributions from NHE1 to pHi regulation [34], limiting
its role in growth at least in the MCF-7 spheroids.
Our work thus corroborates and extends previous
work pointing to the therapeutic potential of inhibiting
acid extruding transporters in breast cancer. However,
several open questions and challenges remain. It is note-
worthy that the impact of NBCn1 knockdown on spheroid
growth appears less dramatic than the strong inhibitory
effect of NBCn1 knockout on growth of chemically in-
duced tumors in vivo [22], and the same appears to be
true for NHE1 knockdown, the effect of which on spher-
oid growth of MDA-MB-231 cells appears to be smaller
than that on their xenograft growth in vivo [36]. This
raises the exciting possibility that the role(s) of the trans-
porters involves additional environmental factors present
in vivo, a question which should be further addressed in
future studies. A challenge is the limited specificity of
some available pharmacological tools, especially problem-
atic for NBCn1, for which currently available drugs are
unspecific and/or unsuitable for tissue use (see [14, 54,
59]). A second challenge illustrated by the present findings
is to determine the relevant transporter(s) to target in a
given cancer, and under which conditions. Clearly, trans-
porter inhibition is likely to be most effective in combin-
ation with other therapeutic modalities, as previously
suggested by findings by us and others [12, 36, 60].
Conclusions
We show here that 3D spheroid growth of MCF-7 breast
cancer cells is associated with polarization, hypoxia gra-
dient induction, and changes in the relative expression
of acid extruding ion transporters NHE1 and NBCn1
relative to 2D growth. Further, we show that individual
pH-regulatory transporters exhibit distinct and differen-
tial expression profiles in breast cancer cell spheroids,
with MCT1 expression following the hypoxia gradient.
(See figure on previous page.)
Fig. 6 Effect of stable knockdown of NHE1, NBCn1 or MCT4 on growth of MDA-MB-231 spheroids. MDA-MB-231 cells were transduced with lentivirus
containing plasmids with shRNA constructs targeted against NHE1, NBCn1 or MCT4. Transduction with the empty vector pLKO.1 (pLKO.1) was used as
control. a: Western blotting with antibodies directed against the specific transporters was performed to verify knockdown of the respective
transporters. b: The transduced cell lines were grown as spheroids, and representative light microscopic images (10×) of the spheroids on day
2, 4, 7 and 9 are shown. Scalebar: 100 μm. 3n. c: Quantification of spheroid diameters shown in b. The dotplot insert shows diameters on day
9. Mean and SEM are indicated. One-way ANOVA with Dunnett’s multiple comparisons post-test was used to test for statistical significant
differences between pLKO.1 and the respective groups. d: NHE1 was transiently knocked down in MDA-MB-231 cells by siRNA interference
and cells were grown as spheroids. Representative light microscopic images (10×) of the spheroids on day 2, 4 and 7 are shown on the right
while quantification of spheroid diameters is shown on the left. Scalebar: 100 μm. 3n. Error bars denote SEM. A two-tailed, paired Student’s
t-test was used to test for statistically significant difference in means between the two groups on day 7. e: NHE1 expression was ablated in
MDA-MB-231 cells by CRISPR/Cas9-mediated knockout (KO) and grown as spheroids for nine days. Left panel shows quantification of spheroid
areas while the right panel shows representative light microscopic images (10×) of the spheroids on day 2, 4, 7 and 9. Scalebar: 100 μm. 3 n.
Error bars denote SEM. WT: wild-type. A two-tailed, unpaired Student’s t-test was used to test for statistically significant difference in means between
the two groups on day 9. * and ** indicate p < 0.05 and p < 0.01, respectively
Andersen et al. Molecular Cancer  (2016) 15:45 Page 15 of 18
Growth of MCF-7 spheroids was predominantly dependent
on MCT1 and NBCs/NBCn1 but was also reduced by
complete NHE1 knockout, whereas growth of MDA-MB-
231 spheroids was predominantly dependent on NHE1.
Endnotes
1Part of these findings have previously been reported
in abstract form [27].
Additional files
Additional file 1: Figure S1. PARP cleavage and CAIX expression on
day 4 and 9 in MCF-7 and MDA-MB-231 spheroids. A: MCF-7 spheroids
grown for 4 and 9 days, respectively, followed by lysis and Western blotting
with PARP antibodies. Top panel shows a representative Western blots,
while lower panel shows quantifications of band intensities normalized to
that of spheroids harvested on day 4. Error bars denote SEM. 3n. A two-
tailed, paired Student’s t-test was used to test for statistically significant
difference in means between the two groups. B: MCF-7 (i) and MDA-MB-231
(ii) spheroids grown for 9 days followed by immunohistochemical staining
with antibodies recognizing cleaved PARP (c-PARP) only. Scalebar: 100 μm.
C: MCF-7 (i) and MDA-MB-231 (ii) spheroids (3D) and 2D cultures grown for
4 and 9 days (spheroids only), respectively, in parallel followed by lysis and
Western blotting with CAIX antibodies. Blots are representative of 3n. In Cii,
right panel shows quantifications of band intensities normalized to that of
spheroids harvested on day 4. Error bars denote SEM. A two-tailed, paired
Student’s t-test was used to test for statistically significant difference in
means between the two groups. ns and * indicate non-significant and p <
0.05, respectively. (PDF 343 kb)
Additional file 2: Figure S2. Transporter distribution across MCF-7
spheroids (individual plots for the data summarized in Fig. 2h). A, B, C, D
and E: Relative distribution of the transporters NHE1, NBCn1, MCT1 and −4,
and Pimonidazole (a marker of hypoxia), respectively, from the periphery
towards the core (across the viable region) of MCF-7 spheroids. Two mean
pixel intensity profiles were made per spheroid, on a total of two-three
spheroids from independent biological replicates per transporter/antibody,
using ImageJ software. Intensity profiles were plotted (black dotted lines)
and LOWESS curves with 20 points in the smoothing window (red lines)
were drawn using Graphpad PRISM 6. (PDF 149 kb)
Additional file 3: Figure S3. NHE1 Ser703 phosphorylation in spheroids
and 2D culture and during spheroid growth. MCF-7 and MDA-MB-231
spheroids (3D) and 2D cultures were grown 4 and 9 (MDA-MB-231 spheroids
only) days in parallel, followed by lysis and Western blotting with antibodies
directed against pSer703-NHE1 and total NHE1. Left and top panels in A and
B, respectively, show representative Western blots, while right and lower
panels, respectively, show quantifications of band intensities normalized to
that of corresponding 2D or 3D culture on day 4. A: MCF-7. Note that the level
of pSer703-NHE1 was normalized to the mean total NHE1 level from five other
experiments (the total NHE1 data shown in Fig. 3a). Data is shown as mean +
SD. 2n. B: MDA-MB-231. Data is shown as mean + SEM. 3n. A two-tailed, paired
Student’s t-test was used to test for statistically significant difference in means
between two groups. * indicates p< 0.05. (PDF 141 kb)
Additional file 4: Figure S4. Effects of pharmacological inhibitors on
transporter expression in 2- and 3D culture. Top panels in A, B, C and D
show representative Western blots of MCF-7 spheroid (3D) and 2D cultures,
respectively, treated with S0859 (50 μM) and AR-C (20 μM) for 2 days/48 h.
Lower panels show quantifications of band intensities normalized to corre-
sponding vehicle control (Ctrl. or DMSO). Data is shown as mean + SEM. A:
NHE1 (4-6n), B: NBCn1 (3n), C: MCT-1 (3n), D: PARP (3n). One-way ANOVA
with Dunnett’s multiple comparisons post-test was used to test for statistical
significant differences between the control and the respective groups. * and
** indicate p-value < 0.05 and p-value < 0.01, respectively. (PDF 250 kb)
Additional file 5: Figure S5. Stability of transient siRNA-mediated
knockdown of NHE1 in MDA-MB-231 cells. A. MDA-MB-231 cells were
transfected with 100 nM siNHE1. 48 h after transfection, cells were
reseeded and the stability of the knockdown in 2D culture was moni-
tored for 120 h. Left panel show Western blots and right panel show
quantifications of band intensities normalized to corresponding Mock
control. B: Western blots showing CRISPR/Cas9-mediated knockout (KO)
of NHE1 in MCF-7 and MDA-MB-231 cells. WT: wild-type. (PDF 135 kb)
Additional file 6: Figure S6. Effect of cariporide on MDA-MB-231
spheroid growth. MDA-MB-231 spheroids were treated with Cariporide
(10 μM) on day 2 and their growth was monitored for seven days (until
day 9). A: Representative light microscopic images (10×) of the spheroids
on day 2, 4, 7, and 9. Numbers in parentheses indicate number of days
treated with the respective inhibitors. Scalebar: 100 μm. B: Quantification of
spheroid diameters shown in A. n= 2-3. Error bars denote SEM. (PDF 275 kb)
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